|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.44 | 89.46 | 104.56 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 0.32 | 0.36 | 0.14 | 2.94 | 53.84 | CEPS(Rs) | 0.29 | 0.32 | 0.03 | 0.26 | 0.33 | DPS(Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Book NAV/Share(Rs) | 3.03 | 2.71 | 23.51 | 23.37 | 192.66 | Tax Rate(%) | 29.12 | 27.83 | 25.00 | 25.76 | 27.03 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 6.58 | -21.02 | -18.89 | 2.25 | 6.51 | EBIT Margin(%) | 21.90 | 15.04 | 2.55 | 6.19 | 6.54 | Pre Tax Margin(%) | 19.83 | 14.65 | 0.29 | 4.44 | 4.49 | PAT Margin (%) | 14.06 | 10.57 | 0.21 | 3.29 | 3.28 | Cash Profit Margin (%) | 14.80 | 11.13 | 0.51 | 3.47 | 3.35 | Performance Ratios | | | | | | ROA(%) | 6.91 | 7.85 | 0.28 | 6.11 | 7.77 | ROE(%) | 11.18 | 14.24 | 0.61 | 17.83 | 32.17 | ROCE(%) | 11.66 | 12.34 | 4.23 | 17.40 | 23.99 | Asset Turnover(x) | 0.49 | 0.74 | 1.28 | 1.86 | 2.37 | Sales/Fixed Asset(x) | 14.76 | 21.25 | 40.52 | 69.51 | 119.69 | Working Capital/Sales(x) | 0.77 | 1.30 | 2.55 | 4.60 | 6.28 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.07 | 0.05 | 0.02 | 0.01 | 0.01 | Receivable days | 303.46 | 223.10 | 122.72 | 92.06 | 77.87 | Inventory Days | 328.71 | 240.43 | 128.19 | 80.57 | 69.21 | Payable days | 5.28 | 18.22 | 50.51 | 66.45 | 54.61 | Valuation Parameters | | | | | | PER(x) | 5.55 | 12.70 | 0.00 | 1.37 | 0.00 | PCE(x) | 6.24 | 14.27 | 0.00 | 15.32 | 0.00 | Price/Book(x) | 0.70 | 2.00 | 0.00 | 2.03 | 0.00 | Yield(%) | 0.00 | 0.00 | 0 | 0.00 | 0 | EV/Net Sales(x) | 1.54 | 2.00 | 0.42 | 0.70 | 0.19 | EV/Core EBITDA(x) | 6.81 | 12.83 | 14.89 | 10.99 | 2.90 | EV/EBIT(x) | 7.04 | 13.31 | 16.64 | 11.31 | 2.93 | EV/CE(x) | 0.76 | 1.46 | 0.63 | 1.07 | 0.42 | M Cap / Sales | 0.92 | 1.59 | 0.00 | 0.53 | 0.00 | Growth Ratio | | | | | | Net Sales Growth(%) | -33.01 | -48.80 | -25.45 | 8.70 | 43.07 | Core EBITDA Growth(%) | -2.82 | 180.24 | -66.64 | 4.69 | 69.07 | EBIT Growth(%) | -2.48 | 201.86 | -69.28 | 2.87 | 69.03 | PAT Growth(%) | -10.92 | 2,420.57 | -95.14 | 9.26 | 81.75 | EPS Growth(%) | -10.92 | 152.06 | -95.14 | -94.53 | 81.75 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.47 | 0.52 | 0.78 | 0.64 | 1.61 | Current Ratio(x) | 2.85 | 2.34 | 2.47 | 1.59 | 1.55 | Quick Ratio(x) | 1.52 | 1.32 | 1.06 | 0.93 | 0.81 | Interest Cover(x) | 10.63 | 38.44 | 1.13 | 3.53 | 3.19 | Total Debt/Mcap(x) | 0.67 | 0.26 | 0 | 0.32 | 0 |
|
|
|
|
|
|